DNTH · NASDAQ
Dianthus Therapeutics (DNTH) Stock Price & Fundamentals
Dianthus Therapeutics (DNTH) closed at $392.87 on Oct 9, 2026, down 0.82% from the previous close of $396.11.
Share price, past year
1Y +6.68%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $392.87 |
| Sep 30, 2026 | $397.57 |
| Aug 31, 2026 | $398.41 |
| Jul 31, 2026 | $400.46 |
| Jun 30, 2026 | $392.21 |
| May 29, 2026 | $372.10 |
| Apr 30, 2026 | $364.20 |
| Mar 31, 2026 | $350.35 |
| Feb 27, 2026 | $372.76 |
| Jan 30, 2026 | $389.73 |
| Dec 31, 2025 | $403.59 |
| Nov 28, 2025 | $399.72 |
| Oct 31, 2025 | $372.87 |
Key statistics
- Market cap
- $21.53B
- P/E (TTM)
- —
- EPS (TTM)
- −$4.25
- Revenue (TTM)
- $2.04M
- Net income (TTM)
- −$192.25M
- Shares outstanding
- 54.8M
- Dividend yield
- —
- 52-week range
- $350.34 – $411.58
Dianthus Therapeutics's market cap is $21.53B, based on a share price of $392.87 and 54.8M shares outstanding as of Jun 30, 2026.
Financials
Dianthus Therapeutics reported revenue of $2.04M for fiscal 2025, down 67.35% from fiscal 2024.
Dianthus Therapeutics reported a net loss of $162.34M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $2.04M | −67.4% | −$162.34M | −7,973.3% | −$4.20 | — |
| FY2024ended Dec 31, 2024 | $6.24M | +120.6% | −$84.97M | −1,362.8% | −$2.55 | — |
| FY2023ended Dec 31, 2023 | $2.83M | — | −$43.56M | −1,541.2% | −$8.45 | — |
| FY2019ended Dec 31, 2019 | $0.00 | — | −$76.77M | — | −$2.07 | −$60.16M |
| FY2018ended Dec 31, 2018 | $0.00 | — | −$57.52M | — | −$3.13 | −$49.56M |
| FY2017ended Dec 31, 2017 | $0.00 | — | −$35.49M | — | −$19.12 | −$24.46M |
| FY2016ended Dec 31, 2016 | $0.00 | — | −$9.43M | — | −$65.15 | −$6.67M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q4 FY2025ended Dec 31, 2025 | $284.00K | −$64.43M | −$1.53 |
| Q3 FY2025ended Sep 30, 2025 | $396.00K | −$36.77M | −$0.97 |
| Q2 FY2025ended Jun 30, 2025 | $193.00K | −$31.63M | −$0.88 |
| Q1 FY2025ended Mar 31, 2025 | $1.16M | −$29.51M | −$0.82 |
| Q4 FY2024ended Dec 31, 2024 | $1.33M | −$28.44M | −$0.76 |
| Q3 FY2024ended Sep 30, 2024 | $2.17M | −$25.17M | −$0.74 |
| Q2 FY2024ended Jun 30, 2024 | $1.86M | — | — |
| Q1 FY2024ended Mar 31, 2024 | $874.00K | — | — |
Company profile
- Name
- Dianthus Therapeutics, Inc. /DE/
- Ticker
- DNTH
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 7 Times Square, 43rd Floor, New York, NY 10036
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001690585
Recent SEC filings
- Aug 4, 2026
- Aug 4, 2026
- Jun 12, 2026
- May 22, 2026
- May 5, 2026
- May 5, 2026
- Mar 26, 2026
- Mar 12, 2026
Frequently asked questions
What is Dianthus Therapeutics's stock price?
Dianthus Therapeutics (DNTH) closed at $392.87 on Oct 9, 2026, down 0.82% from the previous close of $396.11.
What is Dianthus Therapeutics's market cap?
Dianthus Therapeutics's market cap is $21.53B, based on a share price of $392.87 and 54.8M shares outstanding as of Jun 30, 2026.
How much revenue does Dianthus Therapeutics make?
Dianthus Therapeutics reported revenue of $2.04M for fiscal 2025, down 67.35% from fiscal 2024.
Does Dianthus Therapeutics pay a dividend?
Yes. Dianthus Therapeutics declared $0.00 per share in dividends for fiscal 2025.
Sources and methodology
Fundamentals come from Dianthus Therapeutics, Inc. /DE/'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures